Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 2/20 | 0.32 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334217 | 1.00 | LIPE (0.35) | LIPENR1I2ADORA2BSCN9ASCN3A | |
| SCHEMBL7818288 | 0.85 | ADORA2B (0.40) | LIPENR1I2ADORA2BKLK7KMT2A | |
| SCHEMBL6839247 | 0.85 | ADORA2B (0.40) | LIPENR1I2ADORA2BKLK7KMT2A | |
| SCHEMBL6394870 | 0.85 | ADORA2B (0.40) | LIPENR1I2ADORA2BKLK7KMT2A | |
| SCHEMBL6394866 | 0.85 | ADORA2B (0.40) | LIPENR1I2ADORA2BKLK7KMT2A | |
| SCHEMBL4172866 | 0.83 | GPR119 (0.33) | GPR119 | |
| SCHEMBL4172859 | 0.83 | GPR119 (0.33) | GPR119 | |
| SCHEMBL4172864 | 0.83 | GPR119 (0.33) | GPR119 | |
| SCHEMBL4328956 | 0.82 | KCNA3 (0.39) | ADORA2BKMT2AMEN1POLB | |
| SCHEMBL7772596 | 0.82 | ELANE (0.46) | KLK7KLK5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6646123-B2 | Antitumor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030162971-A1 | Pentacyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. | 2003-08-28 | — | — | US | disclosed |
| US-6545151-B2 | Taxol derivative; antitumor agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| US-20010041796-A1 | Pentacyclic compound | TERASAWA HIROFUMI (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-0826688-B1 | PENTACYCLIC COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6211363-B1 | TAXANE COMPOUNDS; ANTITUMOR AGENTS | DAIICHI PHARAMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| US-6075140-A | A TAXOL DERIVATIVE CONTAINING PENTACYCLIC RING IN WHICH 9 AND 10 POSITION HYDROXYL GROUP ARE CHANGED TO CYCLIC ACETAL GROUP IS USEFUL AS ANTITUMOR AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-06-13 | — | — | US | disclosed |
| EP-0826688-A1 | PENTACYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162971-A1 | Pentacyclic compound | RPL31, OXER1, BCOR | LIPE 4563/4885NR1I2 158/4885ADORA2B 2994/4885 |
| US-20010041796-A1 | Pentacyclic compound | RPL31, BCOR, OXER1 | LIPE 4556/4885NR1I2 146/4885ADORA2B 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.